Skip to content

Released Nov 8, 2017, after the close

10-Q filed Nov 8, 2017, 39 days after period end · 0001144204-17-057290

Q3 2017 · 10-Q
Revenue$7.53M+61.2% vs Q3 2016+18.4% vs Q2 2017
Net Income-$11.44MN/M vs Q3 2016N/M vs Q2 2017
EPS Diluted-$0.09N/M vs Q3 2016N/M vs Q2 2017
Gross Profit$1,460,000+246.0%
Operating Income-$7,765,000N/M
Operating Cash Flowderived-$10,539,000N/M
Free Cash Flowderived-$10,677,000N/M
Margins · derived
Gross margin19.4%+10.4 pt vs Q3 2016
Operating margin-103.2%+39.2 pt vs Q3 2016
Net margin-152.0%+4.1 pt vs Q3 2016

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ3 2017Q3 2016Q3 2015Q3 2014
Revenue$7.53M$4.67M$1.34M$2.40M
Net Income-$11.44M-$7.29M-$3.82M-$8.01M
EPS Diluted-$0.09-$0.07-$0.04-$0.09

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR